IL281695A - Degradable hyaluronic acid hydrogels - Google Patents
Degradable hyaluronic acid hydrogelsInfo
- Publication number
- IL281695A IL281695A IL281695A IL28169521A IL281695A IL 281695 A IL281695 A IL 281695A IL 281695 A IL281695 A IL 281695A IL 28169521 A IL28169521 A IL 28169521A IL 281695 A IL281695 A IL 281695A
- Authority
- IL
- Israel
- Prior art keywords
- hyaluronic acid
- acid hydrogels
- degradable
- degradable hyaluronic
- hydrogels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18196869 | 2018-09-26 | ||
| EP19150398 | 2019-01-04 | ||
| EP19181815 | 2019-06-21 | ||
| PCT/EP2019/075884 WO2020064847A1 (en) | 2018-09-26 | 2019-09-25 | Degradable hyaluronic acid hydrogels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL281695A true IL281695A (en) | 2021-05-31 |
Family
ID=68069773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL281695A IL281695A (en) | 2018-09-26 | 2021-03-21 | Degradable hyaluronic acid hydrogels |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210338834A1 (en) |
| EP (1) | EP3856257A1 (en) |
| JP (1) | JP2022502403A (en) |
| CN (1) | CN113164616A (en) |
| AU (1) | AU2019348440A1 (en) |
| CA (1) | CA3114272A1 (en) |
| IL (1) | IL281695A (en) |
| MX (1) | MX2021003184A (en) |
| SG (1) | SG11202101982RA (en) |
| WO (1) | WO2020064847A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111534458B (en) * | 2020-04-13 | 2022-01-14 | 浙江工业大学 | Achromobacter TBC-1 and application thereof in degradation of 1,3,6,8-tetrabromocarbazole |
| AU2021269007A1 (en) | 2020-05-04 | 2022-11-24 | Ascendis Pharma A/S | Hydrogel irradiation |
| BR112023018802A2 (en) | 2021-04-01 | 2023-10-31 | Ascendis Pharma As | USE OF LONG-ACTING GROWTH HORMONE FOR THE TREATMENT OF INFLAMMATION-INDUCED DISEASES |
| WO2024094673A1 (en) | 2022-11-02 | 2024-05-10 | Ascendis Pharma Bone Diseases A/S | Pth treatment regimen comprising two pth compounds |
| CN115710321B (en) * | 2022-11-23 | 2023-10-17 | 浙江千济方医药科技有限公司 | Phellinus linteus polysaccharide and preparation method and application thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL114909A (en) | 1994-08-12 | 1999-10-28 | Immunomedics Inc | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| US7387772B1 (en) | 1999-06-22 | 2008-06-17 | Immunimedics, Inc. | Chimeric, human and humanized anti-CSAP monoclonal antibodies |
| JP3702416B2 (en) | 2000-03-16 | 2005-10-05 | 株式会社日立製作所 | Hydraulic buffer |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| US7151164B2 (en) | 2002-02-14 | 2006-12-19 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| AU2003215732B2 (en) | 2002-03-01 | 2009-12-17 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
| EP2287201B1 (en) | 2002-03-01 | 2018-12-12 | Immunomedics, Inc. | RS7 antibodies |
| EP2301968A3 (en) | 2002-06-14 | 2011-06-29 | Immunomedics, Inc. | Humanized monoclonal antibody HPAM4 |
| WO2004013180A2 (en) | 2002-08-01 | 2004-02-12 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| US7541440B2 (en) | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| EP1620118B1 (en) | 2003-04-08 | 2014-06-18 | Yeda Research And Development Co., Ltd. | Reversible pegylated drugs |
| CA2525788A1 (en) * | 2003-05-15 | 2005-01-06 | University Of Utah Research Foundation | Anti-adhesion composites and methods of use thereof |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
| AU2005232371B2 (en) | 2004-03-23 | 2010-10-14 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
| DK3332808T3 (en) | 2005-03-03 | 2020-12-14 | Immunomedics Inc | Humanized L243 antibodies |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| JP2010503707A (en) | 2006-09-15 | 2010-02-04 | エンゾン ファーマスーティカルズ インコーポレイテッド | Hindered ester biodegradable linkers for oligonucleotide delivery |
| WO2008071447A2 (en) | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| CA2693616A1 (en) | 2007-07-11 | 2009-01-15 | Enzon Pharmaceuticals, Inc. | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
| EP2237799B1 (en) | 2008-02-01 | 2019-04-10 | Ascendis Pharma A/S | Prodrug comprising a self-cleavable linker |
| EP2288261A4 (en) | 2008-05-23 | 2013-09-25 | Enzon Pharmaceuticals Inc | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
| EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
| IN2012DN01663A (en) | 2009-09-16 | 2015-06-05 | Immunomedics Inc | |
| US20120289571A1 (en) | 2009-12-31 | 2012-11-15 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
| DK2525830T3 (en) | 2010-01-22 | 2016-08-15 | Ascendis Pharma As | DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES |
| EP2525829A1 (en) | 2010-01-22 | 2012-11-28 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| US9561285B2 (en) | 2010-01-22 | 2017-02-07 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
| CN103025165B (en) | 2010-05-05 | 2016-06-08 | 普罗林科斯有限责任公司 | From the controlled release of macromolecular conjugates |
| WO2011140392A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from solid supports |
| EP3643306A3 (en) | 2011-08-12 | 2020-08-26 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
| WO2013024052A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Carrier-linked treprostinil prodrugs |
| WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
| WO2013160340A1 (en) | 2012-04-25 | 2013-10-31 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| US11633487B2 (en) | 2014-08-06 | 2023-04-25 | Ascendis Pharma A/S | Prodrugs comprising an aminoalkyl glycine linker |
| AR105319A1 (en) * | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
| KR101818705B1 (en) * | 2015-07-20 | 2018-01-16 | 포항공과대학교 산학협력단 | Cross-linked hyaluronic acid hydrogel encapsulating therapeutic drugs and uses thereof |
| CN116987187A (en) | 2015-09-23 | 2023-11-03 | 豪夫迈·罗氏有限公司 | Optimized variants of anti-VEGF antibodies |
| UA121914C2 (en) | 2015-11-18 | 2020-08-10 | Мерк Шарп І Доум Корп. | Pd1 and/or lag3 binders |
| AU2016355569B2 (en) | 2015-11-18 | 2020-01-02 | Merck Sharp & Dohme Llc | CTLA4 binders |
| CN110891611B (en) * | 2017-03-22 | 2024-03-29 | 阿森迪斯制药公司 | Hydrogel crosslinked hyaluronic acid prodrug compositions and methods |
-
2019
- 2019-09-25 JP JP2021516900A patent/JP2022502403A/en active Pending
- 2019-09-25 US US17/280,760 patent/US20210338834A1/en active Pending
- 2019-09-25 WO PCT/EP2019/075884 patent/WO2020064847A1/en unknown
- 2019-09-25 SG SG11202101982RA patent/SG11202101982RA/en unknown
- 2019-09-25 CA CA3114272A patent/CA3114272A1/en active Pending
- 2019-09-25 MX MX2021003184A patent/MX2021003184A/en unknown
- 2019-09-25 CN CN201980078088.XA patent/CN113164616A/en active Pending
- 2019-09-25 AU AU2019348440A patent/AU2019348440A1/en active Pending
- 2019-09-25 EP EP19778496.0A patent/EP3856257A1/en active Pending
-
2021
- 2021-03-21 IL IL281695A patent/IL281695A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3856257A1 (en) | 2021-08-04 |
| JP2022502403A (en) | 2022-01-11 |
| WO2020064847A1 (en) | 2020-04-02 |
| CA3114272A1 (en) | 2020-04-02 |
| SG11202101982RA (en) | 2021-03-30 |
| MX2021003184A (en) | 2021-08-11 |
| AU2019348440A1 (en) | 2021-03-25 |
| CN113164616A (en) | 2021-07-23 |
| US20210338834A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269506A (en) | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods | |
| IL257024B (en) | Injectable macroporous hydrogels | |
| IL281695A (en) | Degradable hyaluronic acid hydrogels | |
| EP3900751A4 (en) | Filler having excellent filler properties comprising hyaluronic acid hydrogel | |
| EP3473242A4 (en) | Hyaluronic acid microstructure having excellent solubility characteristics | |
| IL279445A (en) | Stabilized hyaluronic acid | |
| GB201810788D0 (en) | Biodegradable polymer | |
| GB201620204D0 (en) | Hydrogels | |
| PL3649164T3 (en) | Modified polymer polyols | |
| IL278933A (en) | Tlr7 agonists | |
| IL281690A (en) | Novel hydrogel conjugates | |
| EP3307338A4 (en) | Novel hyaluronic acid-based hydrogels having medical applications | |
| PL3623262T3 (en) | Semi-trailer | |
| EP3700589A4 (en) | Temperature-responsive degradable hydrogels | |
| EP3640270A4 (en) | Lipoic acid hydrogels | |
| EP3861039C0 (en) | Hydrogel compositions | |
| GB201917656D0 (en) | Polymer | |
| GB202100709D0 (en) | Polymer composition | |
| EP3760337A4 (en) | Molding facility | |
| EP3658591A4 (en) | Polydicarboxylic acid based dispesant | |
| EP3571617A4 (en) | Updating firmware | |
| EP3115378A4 (en) | Hyaluronic acid modified by sphingosine-1-phosphoric acid | |
| TWI845521B (en) | Aptamer formulation | |
| EP3844241C0 (en) | Hydrogel | |
| GB201900815D0 (en) | Polymer |